Literature DB >> 20089384

Metabolic syndrome in children with Prader-Willi syndrome: the effect of obesity.

P Brambilla1, A Crinò, G Bedogni, L Bosio, M Cappa, A Corrias, M Delvecchio, S Di Candia, L Gargantini, E Grechi, L Iughetti, A Mussa, L Ragusa, M Sacco, A Salvatoni, G Chiumello, G Grugni.   

Abstract

BACKGROUND AND AIMS: Prader-Willi syndrome (PWS), the most frequent syndromic obesity, is associated with elevated morbidity and mortality in pediatric and adult ages. In PWS, the presence of metabolic syndrome (MS) has not yet been established. The aim of the study was to estimate the frequency of MS and its components in pediatric subjects according to obesity status. METHODS AND
RESULTS: A cross-sectional study was performed in 109 PWS children aged 2-18 years (50 obese and 59 non-obese) and in 96 simple obese controls matched for age, gender, and also for BMI with obese PWS. Obesity was defined when SDS-BMI was >2. Non-obese PWS showed significantly lower frequency of hypertension (12%) than obese PWS (32%) and obese controls (35%)(p=0.003). The same was observed for low HDL-cholesterol (3% vs 18% and 24%, p=0.001) and high triglycerides (7% vs 23% and 16%, p=0.026). Frequency of altered glucose metabolism was not different among groups (2% vs 10% and 5%), but type 2 diabetes (four cases) was present only in obese PWS. Non-obese PWS showed lower insulin and HOMA-index respect to obese PWS and obese controls (p ≤ 0.017). Overall MS frequency in PWS was 7.3%. None of the non-obese PWS showed MS compared with 16% of obese PWS and controls (p<0.001). When obesity was excluded from the analysis, a significantly lower frequency for clustering of ≥ 2 factors was still found in non-obese PWS (p=0.035).
CONCLUSION: Non-obese PWS showed low frequency of MS and its components, while that observed in obese PWS was very close to those of obese controls, suggesting the crucial role of obesity status. Prevention of obesity onset remains the most important goal of PWS treatment. Early identification of MS could be helpful to improve morbidity and mortality in such patients.
Copyright © 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089384     DOI: 10.1016/j.numecd.2009.10.004

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  19 in total

Review 1.  Review of Prader-Willi syndrome: the endocrine approach.

Authors:  Ryan Heksch; Manmohan Kamboj; Kathryn Anglin; Kathryn Obrynba
Journal:  Transl Pediatr       Date:  2017-10

2.  Does segmental body composition differ in women with Prader-Willi syndrome compared to women with essential obesity?

Authors:  G Bedogni; G Grugni; G Tringali; N Marazzi; A Sartorio
Journal:  J Endocrinol Invest       Date:  2015-04-04       Impact factor: 4.256

Review 3.  Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome.

Authors:  Antonino Crinò; Graziano Grugni
Journal:  Curr Diab Rep       Date:  2020-02-06       Impact factor: 4.810

4.  Early Detection and Management of Prader-Willi Syndrome in Egyptian Patients.

Authors:  Hala T El-Bassyouni; Nagwa Hassan; Inas Mahfouz; Azza E Abd-Elnaby; Mostafa I Mostafa; Angie M S Tosson
Journal:  J Pediatr Genet       Date:  2019-08-04

Review 5.  Prader- Willi syndrome: An uptodate on endocrine and metabolic complications.

Authors:  Giovanna Muscogiuri; Gloria Formoso; Gabriella Pugliese; Rosaria Maddalena Ruggeri; Elisabetta Scarano; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2019-06       Impact factor: 6.514

Review 6.  Prader-Willi Syndrome in Adults: An Update On Nutritional Treatment and Pharmacological Approach.

Authors:  Silvia Savastano; Giovanna Muscogiuri; Luigi Barrea; Claudia Vetrani; Danilo Fintini; Giulia de Alteriis; Filippo Maria Panfili; Sarah Bocchini; Ludovica Verde; Annamaria Colao
Journal:  Curr Obes Rep       Date:  2022-09-05

7.  Circulating Irisin in Children and Adolescents With Prader-Willi Syndrome: Relation With Glucose Metabolism.

Authors:  Stefania Mai; Danilo Fintini; Chiara Mele; Alessio Convertino; Sarah Bocchini; Graziano Grugni; Gianluca Aimaretti; Roberta Vietti; Massimo Scacchi; Antonino Crinò; Paolo Marzullo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-14       Impact factor: 6.055

8.  Experience of severe desaturation during anesthetic induction period in an obese adult patient with Prader-Willi syndrome -A case report-.

Authors:  Joon Woo Choi; Eun-Ju Kim; Byung Woo Min; Jong Seouk Ban; Sang Gon Lee; Ji-Hyang Lee
Journal:  Korean J Anesthesiol       Date:  2012-02-20

Review 9.  GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.

Authors:  Cheri L Deal; Michèle Tony; Charlotte Höybye; David B Allen; Maïthé Tauber; Jens Sandahl Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

Review 10.  Obesity management in Prader-Willi syndrome: current perspectives.

Authors:  Antonino Crinò; Danilo Fintini; Sarah Bocchini; Graziano Grugni
Journal:  Diabetes Metab Syndr Obes       Date:  2018-10-04       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.